CD274 and Miyoshi myopathy: In the immunotherapy of MM patients, except pembrolizumab, several other ICIs have been administered, including nivolumab (anti-PD-1 mAb) and atezolizumab (anti-PD-L1 mAb) alone, or in combination with conventional chemotherapeutics and/or IMIDs, which are showing a disappointing clinical response in the majority of cases [23,55].